empty
 
 
hu
Keresés
Támogatás
Azonnali számlanyitás
Trading Platform
Befizetés/pénzfelvétel
Keresés
Kezdőknek Kereskedőknek Partnereknek Tartson egy kis szünetet Az InstaForexrol
hu
#BMY Return to the list of instruments #CGC

Currency converter

BioNTech SE
98.62 USD
08 Sep 2026 21:59
Price Change (% chg)
$0.1
(0.10%)
Prev Close
Prev Close

Closing price, the previous day.
$98.62
Open
Open

Opening price.
$103.26
Day's High
Day's High

The highest price over the last trading day.
$98.62
Day's Low
Day's Low

The lowest price over the last trading day
$98.62
Week High
Week High

Price range high in the last week
$101.36
Week Low
Week Low

Price range low in the last week
$98.62
Download archive
Buy
100.12
Sell
98.62
Open the chart in full screen view
Buy
100.12
Sell
98.62
Download archive
Open the chart in full screen view

BioNTech SE. About company

BioNTech SE. is a biotechnology company founded in 2008 in Germany. It develops medicines for the treatment of cancer, HIV, tuberculosis, and other diseases.

In 2020, BioNTech SE. participated in the creation of a COVID-19 vaccine together with Pfizer and Fosun Pharma. As of March 2022, BioNTech SE. and Pfizer have delivered more than 3.1 billion doses of vaccines.

The company owns a factory in Marburg but most of the vaccines are produced at Pfizer and other companies' factories. In 2021, BioNTech SE. announced its plan to open its first vaccine manufacturing facility in Rwanda.

Its market cap currently stands at $33.38 billion. In 2021, its revenue amounted to $18,976 billion. The net profit totaled $10,292 billion.

BioNTech SE. shares and what factors impact them

BioNTech SE. stock has been traded on the NASDAQ exchange under the BNTX ticker since 2019. The initial price was $15.

Nowadays, the stock price is estimated at $135-$138. Over the year, it fluctuated in the range of $117 - $370.

In 2022, the company paid dividends to the shareholders in the amount of $2.11 per share. The yield was 1.65%.

You should pay attention to the following factors when trading its stock:

  • News about rivals that produce medicines and vaccines;
  • Likelihood of a high profit from the development of an Omicron vaccine;
  • Dependence on government agencies that regulate the industry and the production of coronavirus vaccines.

Can't speak right now?
Ask your question in the chat.